The hair relaxer lawsuit has consolidated into one of the largest active product liability proceedings in the country, and the latest update is that more than 10,000 individual claims now sit before a single federal judge in Chicago. The case is called MDL 3060, and 2026 is the year that decides whether it moves toward trial or falls apart. No jury will hear a bellwether case before 2027, but the expert battles happening this year will determine whether that trial ever happens and what any settlement might look like.
Where the Cases Stand Today
Every federal hair relaxer case in the country has been transferred to the Northern District of Illinois and consolidated as MDL No. 3060.1United States Judicial Panel on Multidistrict Litigation. In Re Hair Relaxer Marketing Sales Practices and Products Liability Litigation – Transfer Order Judge Mary Rowland oversees the docket, which has grown past 10,000 filed cases. One judge decides all the shared pretrial questions; each plaintiff still keeps her own separate damages claim.
The MDL continues to accept new filings, but the bellwether pool has already been fixed and deadlines are tightening. Timing now matters more than it did a year ago.
Who Is Being Sued
The litigation names more than a dozen corporate defendants. The most prominent are L’Oréal USA, SoftSheen-Carson, Revlon, Namaste Laboratories, Strength of Nature, and Dabur International.1United States Judicial Panel on Multidistrict Litigation. In Re Hair Relaxer Marketing Sales Practices and Products Liability Litigation – Transfer Order Smaller manufacturers named include Luster Products, McBride Research Laboratories, and AFAM Concept (doing business as JF Labs).
The product lines most frequently cited include Dark & Lovely, Optimum Salon Haircare, Ultra Sheen, and several other at-home relaxer kits sold under the SoftSheen-Carson umbrella. Plaintiffs allege these products were marketed heavily to Black women for decades without adequate disclosure of cancer risk.
The Ruling That Kept the Case Alive
On November 13, 2023, Judge Rowland ruled on the defendants’ motion to dismiss the Master Complaint. Of 15 legal claims, 12 survived.2Justia. In Re Hair Relaxer Marketing Sales Practices and Products Liability Litigation The surviving theories include strict liability for design defect, strict liability for failure to warn, negligence and gross negligence, breach of implied and express warranties, unjust enrichment, wrongful death and survival actions, loss of consortium, and punitive damages.
The defendants also argued that federal cosmetics law preempted state product liability claims entirely. The court rejected that argument, relying on a provision in the Federal Food, Drug, and Cosmetic Act that preserves state-level product liability actions. A lot of product liability MDLs die on preemption early on. This one didn’t.
The 2026 Calendar
Bellwether trials are the test cases both sides use to gauge how juries react to the evidence, and their outcomes typically drive global settlement talks. Judge Rowland expanded the bellwether pool to 40 cases for discovery, with up to 12 potentially going to trial.3Nigh Goldenberg Raso & Vaughn. Case Management Order No 15 – Bellwether Selection Schedule and Procedure The 2026 schedule includes:
- February 16, 2026: fact discovery closes for the 32 initial bellwether discovery cases.
- February 23 through March 18, 2026: the court selects 10 potential bellwether trial cases.
- March 2, 2026: general causation expert discovery closes.
- April 1, 2026: defendants file Daubert motions challenging plaintiffs’ general causation experts.
- May 1, 2026: oppositions to Daubert motions due; additional bellwether trial case discovery closes.
- June 30, 2026: plaintiffs disclose case-specific expert reports.
- August 3, 2026: defendants disclose case-specific expert reports.
- October 16, 2026: all case-specific expert discovery concludes.
- November 16, 2026: deadline for summary judgment and remaining Daubert motions.
Why April 1 Is the Turning Point
The April 2026 Daubert motions on general causation are the single most consequential event in this litigation. General causation asks whether hair relaxer chemicals are capable of causing cancer at all. If the court excludes plaintiffs’ experts on that question, the entire MDL effectively collapses. If the experts survive, defendants face heavy pressure to negotiate rather than risk 12 jury verdicts. Defendants have been allotted up to 100 pages to challenge plaintiffs’ 10 general causation experts, with plaintiffs receiving equal space to respond.3Nigh Goldenberg Raso & Vaughn. Case Management Order No 15 – Bellwether Selection Schedule and Procedure
Which Diagnoses Qualify
The MDL currently focuses on three cancer diagnoses linked to hair relaxer use:
- Uterine cancer
- Endometrial cancer (cancer of the uterine lining, sometimes classified as a subtype of uterine cancer)
- Ovarian cancer
For bellwether eligibility, the court narrowed the pool to cases involving these three cancers where plaintiffs had filed and served short-form complaints by February 1, 2024. That filter reduced the eligible cases to approximately 5,230.
Uterine fibroids and endometriosis are not recognized as qualifying conditions in the MDL, even though some attorneys initially evaluated them. The scientific evidence tying relaxer chemicals to cancer specifically defined the litigation’s scope.
How to File a Claim
Joining the litigation requires filing a Short Form Complaint through the court’s electronic case management system. That document lets you adopt the allegations in the Master Complaint without rewriting the legal theory from scratch, and you specify your own injuries, the products you used, and which defendants you are suing.4United States District Court for the Northern District of Illinois. Short-Form Complaint and Jury Demand A filing fee accompanies the complaint, and the case receives a unique docket number within MDL 3060.
After filing, every plaintiff must complete a Plaintiff Fact Sheet. This standardized form collects detailed information about your relaxer use: which brands, how often, at what age you started, and for how long.5United States District Court Northern District of Illinois. Plaintiff Fact Sheet – In Re Hair Relaxer Marketing Sales Practices and Products Liability Litigation It also requires a complete medical history including diagnosis and treatment records. Missing the fact sheet deadline can get your case dismissed, so this is not optional paperwork.
Evidence Worth Gathering Now
The strongest claims document both the diagnosis and the pattern of product use. Useful evidence includes:
- Pathology reports confirming a qualifying cancer diagnosis, along with treatment and surgical records.
- Product use history: receipts, credit card statements, salon records, photographs, or statements from hairstylists who applied the products.
- Timeline documentation showing when you started using relaxers and how often, since the NIH’s Sister Study found elevated risk specifically among women who used the products four or more times per year.6National Institutes of Health. Hair Straightening Chemicals Associated With Higher Uterine Cancer Risk
Most women who used relaxers for decades didn’t keep receipts. That’s normal. Statements from family, friends, or salon professionals confirming long-term use can fill the gaps.
The Deadline Problem You Can’t Ignore
Product liability claims carry filing deadlines that vary by state, typically ranging from one to six years depending on the jurisdiction and the type of claim. Most states apply a discovery rule, meaning the clock starts when you knew or reasonably should have known that your injury was connected to the product. For hair relaxer claims, that usually means the statute of limitations began when you learned about the potential link between relaxers and cancer, not when you were first diagnosed or first used the product.
The October 2022 NIH study made that link widely public. In states with a two-year discovery-rule window, a plaintiff who took no action by late 2024 may already face a time-bar argument from defendants. If you have a qualifying diagnosis and haven’t filed, the statute of limitations is the first question to resolve. Waiting for a settlement announcement before filing is a common and costly mistake.
The FDA’s Parallel Track
Separate from the litigation, the FDA has moved toward banning formaldehyde and formaldehyde-releasing chemicals in hair straightening and smoothing products. The agency initiated a proposed rulemaking citing both short-term health effects like breathing problems and long-term cancer risk.7Reginfo.gov. Use of Formaldehyde and Formaldehyde-Releasing Chemicals as an Ingredient in Hair Smoothing Products or Hair Straightening Products The proposed rule was listed for a Notice of Proposed Rulemaking in 2024, though the final implementation timeline remains uncertain.
An FDA ban would remove one category of harmful chemicals from the market going forward. It would not compensate anyone already harmed. The regulatory action and the litigation move on separate tracks, though a finalized ban would reinforce plaintiffs’ argument that the chemicals were dangerous and that manufacturers should have acted sooner.
What a Settlement Would Mean at Tax Time
No global settlement has been reached in MDL 3060, and none is likely before bellwether trials produce results. The tax picture still matters because it affects the real value of any future award.
Under federal tax law, compensatory damages received for personal physical injuries or physical sickness are excluded from gross income.8Office of the Law Revision Counsel. 26 USC 104 – Compensation for Injuries or Sickness For plaintiffs alleging a product caused cancer, that means compensation for the cancer itself, related pain and suffering, medical expenses, and lost wages would generally not be taxable. The IRS evaluates taxability based on what the payment actually compensates, not how the settlement agreement is labeled.9Internal Revenue Service. Tax Implications of Settlements and Judgments
Some categories are treated differently. Punitive damages are almost always taxable, even in a personal physical injury case. Interest that accrues on a judgment before or after trial is also taxable. And if you previously deducted medical expenses on a tax return and later receive settlement funds reimbursing those same costs, the reimbursed portion may be taxable under the tax-benefit rule.9Internal Revenue Service. Tax Implications of Settlements and Judgments Given the potential size of individual awards, a tax professional’s review before accepting any offer is worth the cost.